Abstract
Elevated levels of serum ferritin (SF) are observed in several types of cancer; however, little is known on the association between ferritin and glioma, the most frequent type of human primary brain tumour. Here we report that GBM patients show significantly increased pre-surgical SF levels (i.e. ferritinaemia) within the SF reference range and a marked ferritin immunoreactivity of resected tumour tissue. Our findings account for an indirect association between ferritin synthesis in glioma-tissue and altered SF levels, which limits the clinical value of SF as a tumour marker in glioma. Importantly, we show for the first time that GBM-derived glioma cells release ferritin in vitro, which exerts an apoptosis-stimulating activity. Albeit the pathophysiologic context of apoptosis induction by a tumour-derived ferritin remains to be defined, our findings account for a distinct growth-regulatory role of these ferritin species in tumour biology.
| Original language | English |
|---|---|
| Pages (from-to) | 1441-1444 |
| Number of pages | 4 |
| Journal | British Journal of Cancer |
| Volume | 122 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 12 May 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fields of science
- 301 Medical-Theoretical Sciences, Pharmacy
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver